Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Stoke Therapeutics, Inc. (STOK : NSDQ)

• Company Description    Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts. Number of Employees: 128

• Price / Volume Information    Yesterday's Closing Price: $11.48 Daily Weekly Monthly 20 Day Moving Average: 488,363 shares Shares Outstanding: 54.60 (millions) Market Capitalization: $626.77 (millions) Beta: 1.14 52 Week High: $16.15 52 Week Low: $5.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.05% -1.53% 12 Week 63.53% 39.68% Year To Date 4.08% -2.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 45 WIGGINS AVENUE - BEDFORD,MA 01730 USA ph: 781-430-8200 fax: - ir@stoketherapeutics.com http://www.stoketherapeutics.com

• General Corporate Information    Officers Edward M. Kaye - Chief Executive Officer Thomas E. Leggett - Chief Financial Officer Julie A. Smith - Director Adrian R. Krainer - Director Jennifer C. Burstein - Director Peer Information Stoke Therapeutics, Inc. (CORR.) Stoke Therapeutics, Inc. (RSPI) Stoke Therapeutics, Inc. (CGXP) Stoke Therapeutics, Inc. (BGEN) Stoke Therapeutics, Inc. (GTBP) Stoke Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 86150R107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 54.60 Most Recent Split Date: (:1) Beta: 1.14 Market Capitalization: $626.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.14 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 14.53 PEG Ratio: - Price Ratios Price/Book: 1.79 Price/Cash Flow: - Price / Sales: 3.28 EPS Growth vs. Year Ago Period: 433.33% vs. Previous Quarter: 1,155.56% Sales Growth vs. Year Ago Period: 3,661.12% vs. Previous Quarter: 601.20% ROE 06/30/25 - - 03/31/25 - 19.08 12/31/24 - -42.16 ROA 06/30/25 - - 03/31/25 - 15.72 12/31/24 - -33.02 Current Ratio 06/30/25 - - 03/31/25 - 8.41 12/31/24 - 5.81 Quick Ratio 06/30/25 - - 03/31/25 - 8.41 12/31/24 - 5.81 Operating Margin 06/30/25 - - 03/31/25 - 26.33 12/31/24 - -243.42 Net Margin 06/30/25 - - 03/31/25 - 26.33 12/31/24 - -243.42 Pre-Tax Margin 06/30/25 - - 03/31/25 - 27.00 12/31/24 - -243.42 Book Value 06/30/25 - - 03/31/25 - 6.41 12/31/24 - 4.32 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©